Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Contrast-enhanced MRI is not harmful - doubts about MRI lifted

Contrast-enhanced MRI is not harmful - doubts about MRI lifted

What is magnetic resonance (MR) ?

Magnetic resonance (MR) is an imaging method based on hydrogen atoms in water molecules responding to a magnetic field, used safely because it involves no radiation. It is known as the radiological method best depicting organ anatomy. Not using drugs that may cause allergy during imaging MRis an important advantage, but contrast-enhanced MR is preferred in certain situations, particularly suspected cancer or monitoring cancer patients. In recent years, magnetic resonance imaging using gadolinium contrast has been criticized because of potential side effects and claimed harm to health.

Gadolinium is a heavy metal retained not only in the brain but also in skin and bone. Gadolinium-based contrast agents (GBCA) are preferred because they substantially improve image quality in MR examinations detailing organs, soft tissues and vessels.

Is contrast-enhanced MR harmful ?

The first health-related complaint came from Japan in 2014, claiming that after several examinations using gadolinium-based contrast, MR people had increased brain signal intensity. Mayo Clinic in America later issued another supporting statement. Its study, covering 2000 to 2014, examined people who had at least four GBCA-enhanced MR scans , totaling 13 patients examined after death. It reported an association with gadolinium accumulation in neuronal tissue samples compared with noncontrast MR patients. The American Food and Drug Administration (FDA) then began monitoring gadolinium-based contrast for health effects in 2015.

After approximately two years of investigation, the FDA reported no evidence of harm caused by gadolinium retention in the brain after MR scans using gadolinium-based contrast. Its statement did not restrict contrast use in MR, but added that it would continue investigating these agents' safety.

Two months later, in July 2017, differing from the FDA decision, the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) found convincing evidence of gadolinium deposits in brain tissue months after use of three contrast agents, recommending restricted use following these confirmed findings. The EMA specifically announced suspension of authorization for three intravenous linear gadolinium agents: Magnevist (gadopentetic acid), Omniscan (gadodiamide) and OPTIMARK (gadoversetamide).

The EMA stated the restriction recommendation was precautionary only, with no clear evidence that brain accumulation posed a health risk. The European Commission would next review its recommendations and make a legally binding decision.

Ultimately, particularly for people undergoing multiple (four or more) contrast-enhanced MR scans, these warnings were not based on any proven adverse health effect. However, as with everything, they matter for limiting unnecessary examinations. Your doctor can provide the most accurate information about the benefits and harms to you of requested tests.

Sources

1. No Harm Seen in MRI Gadolinium Retention in Brain, FDA Says.
medscape.com

2. Kanda T, Ishii K, Kawaguchi H ve ark.
High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material.
Radiology. 2014

3. McDonald RJ, McDonald JS, Kallmes DF ve ark.
Intracranial gadolinium deposition after contrast-enhanced MR imaging.
Radiology. 2015

4. Gadolinium-Based Contrast Agents and Brain Safety: Signal vs Noise
medscape.com

5. EMA Recommends Suspending Certain Gadolinium Contrast Agents;
raps.org

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Contrast-enhanced MRI is not harmful - doubts about MRI lifted

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy